Novel blood pressure locus and gene discovery using GWAS and expression datasets from blood and the kidney

Running title: Novel blood pressure locus and gene discovery

Louise V. Wain[1], Ahmad Vaez[2,3], Rick Jansen[4], Roby Joehanes[5,6], Peter J. van der Most[2], A. Mesut Erzurumluoglu[1], Paul O'Reilly[7], Claudia P. Cabrera[8,9], Helen R. Warren[8,9], Lynda M. Rose[10], Germaine C. Verwoert[11], Jouke-Jan Hottenga[12], Rona J. Strawbridge[13,14], Tonu Esko[15,16,17], Dan E. Arking[18], Shih-Jen Hwang[19,20], Xiuqing Guo[21], Zoltan Kutalik[22,23], Stella Trompet[24,25], Nick Shrine[1], Alexander Teumer[26,27], Janina S. Ried[28], Joshua C. Bis[29], Albert V. Smith[30,31], Najaf Amin[32], Ilja M. Nolte[2], Leo-Pekka Lyytikäinen[33,34], Anubha Mahajan[35], Nicholas J. Wareham[36], Edith Hofer[37,38], Peter K. Joshi[39], Kati Kristiansson[40], Michela Traglia[41], Aki S. Havulinna[40], Anuj Goel[42,35], Mike A. Nalls[43,44], Siim Sõber[45], Dragana Vuckovic[46,47], Jian'an Luan[36], Fabiola Del Greco M.[48], Kristin L. Ayers[49], Jaume Marrugat[50], Daniela Ruggiero[51], Lorna M. Lopez[52,53,54], Teemu Niiranen[40], Stefan Enroth[55], Anne U. Jackson[56], Christopher P. Nelson[57,58], Jennifer E. Huffman[59], Weihua Zhang[60,61], Jonathan Marten[62], Ilaria Gandin[47], Sarah E Harris[52,63], Tatijana Zemunik[64], Yingchang Lu[65], Evangelos Evangelou[60,66], Nabi Shah[67,68], Martin H. de Borst[69], Massimo Mangino[70,71], Bram P. Prins[72], Archie Campbell[73,74], Ruifang Li-Gao[75], Ganesh Chauhan[76,77], Christopher Oldmeadow[78], Gonçalo Abecasis[79], Maryam Abedi[80], Caterina M. Barbieri[41], Michael R. Barnes[8,9], Chiara Batini[1], John Beilby[81,82,83], BIOS Consortium[84], Tineka Blake[1], Michael Boehnke[56], Erwin P. Bottinger[65], Peter S. Braund[57,58], Morris Brown[8,9], Marco Brumat[47], Harry Campbell[39], John C. Chambers[60,61,85], Massimiliano Cocca[47], Francis Collins[86], John Connell[87], Heather J. Cordell[88], Jeffrey J. Damman[89], Gail Davies[52,90], Eco J. de Geus[12], Renée de Mutsert[75], Joris Deelen[91], Yusuf Demirkale[92], Alex S.F. Doney[67], Marcus Dörr[93,27], Martin Farrall[42,35], Teresa Ferreira[35], Mattias Frånberg[13,14,94], He Gao[60], Vilmantas Giedraitis[95], Christian Gieger[96], Franco

Giulianini[10], Alan J. Gow[52,97], Anders Hamsten[13,14], Tamara B. Harris[98], Albert Hofman[11,99], Elizabeth G. Holliday[78], Jennie Hui[81,82,100,83], Marjo-Riitta Jarvelin[101,102,103,104], Åsa Johansson[55], Andrew D. Johnson[6,105], Pekka Jousilahti[40], Antti Jula[40], Mika Kähönen[106,107], Sekar Kathiresan[108,109,110], Kay-Tee Khaw[111], Ivana Kolcic[112], Seppo Koskinen[40], Claudia Langenberg[36], Marty Larson[6], Lenore J. Launer[98], Benjamin Lehne[60], David C.M. Liewald[52,90], Lifelines Cohort Study[113], Li Lin[114], Lars Lind[115], François Mach[114], Chrysovalanto Mamasoula[116], Cristina Menni[70], Borbala Mifsud[8], Yuri Milaneschi[117], Anna Morgan[47], Andrew D. Morris[118], Alanna C. Morrison[119], Peter J. Munson[92], Priyanka Nandakumar[18], Quang Tri Nguyen[92], Teresa Nutile[51], Albertine J. Oldehinkel[120], Ben A. Oostra[32], Elin Org[15], Sandosh Padmanabhan[121,74], Aarno Palotie[122], Guillaume Paré[123], Alison Pattie[90], Brenda W.J.H. Penninx[117], Neil Poulter[124], Peter P. Pramstaller[48,125,126], Olli T. Raitakari[127,128], Meixia Ren[8,129], Kenneth Rice[130], Paul M. Ridker[10,131], Harriëtte Riese[120], Samuli Ripatti[122], Antonietta Robino[132], Jerome I. Rotter[133], Igor Rudan[39], Yasaman Saba[134], Aude Saint Pierre[48,135], Cinzia F. Sala[41], Antti-Pekka Sarin[122], Reinhold Schmidt[37], Rodney Scott[78,136,137], Marc A. Seelen[69], Denis C. Shields[138], David Siscovick[139], Rossella Sorice[51,140], Alice Stanton[141], David J. Stott[142], Johan Sundström[115], Morris Swertz[143], Kent D. Taylor[144,145], Simon Thom[146], Ioanna Tzoulaki[60], Christophe Tzourio[76,77,147], André G. Uitterlinden[11,148], Understanding Society Scientific group[84], Uwe Völker[149,27], Peter Vollenweider[150], Sarah Wild[39], Gonneke Willemsen[12], Alan F. Wright[62], Jie Yao[21], Sébastien Thériault[123], David Conen[151], Attia John[78,136,137], Peter Sever[152], Stéphanie Debette[76,77,153], Dennis O. Mook-Kanamori[75,154], Eleftheria Zeggini[72], Tim D. Spector[70], Pim van der Harst[155], Colin N.A. Palmer[67], Anne-Claire Vergnaud[60], Ruth J.F. Loos[36,156,157], Ozren Polasek[112], John M. Starr[52,158], Giorgia Girotto[47,46], Caroline Hayward[159,74], Jaspal S. Kooner[160,61,85], Cecila M. Lindgren[17,35], Veronique Vitart[59], Nilesh J. Samani[57,58], Jaakko Tuomilehto[161,162,163,164], Ulf Gyllensten[55], Paul Knekt[40], Ian J. Deary[52,90], Marina Ciullo[51,140], Roberto Elosua[50], Bernard D. Keavney[165], Andrew A. Hicks[48], Robert A. Scott[36], Paolo Gasparini[46,47], Maris Laan[45,166], YongMei Liu[167], Hugh Watkins[42,35], Catharina A. Hartman[120], Veikko Salomaa[40], Daniela Toniolo[41], Markus Perola[40,122,168], James F. Wilson[39,62], Helena Schmidt[134,169], Jing Hua Zhao[36], Terho Lehtimäki[33,34], Cornelia M. van Duijn[32], Vilmundur Gudnason[30,31], Bruce M. Psaty[29,170,171,172], Annette Peters[28], Rainer Rettig[173], Alan James[174,175], J Wouter Jukema[24], David P. Strachan[176], Walter Palmas[177], Andres Metspalu[15], Erik Ingelsson[178,179], Dorret I. Boomsma[12], Oscar H. Franco[11], Murielle Bochud[22], Christopher Newton-Cheh[180,108,110,17],

Patricia B. Munroe[8,9], Paul Elliott[104], Daniel I. Chasman[10,131], Aravinda Chakravarti[18], Joanne Knight[181], Andrew P. Morris[182,35], Daniel Levy[183,20], Martin D. Tobin[1], Harold Snieder[2*], Mark J. Caulfield[8,9*], Georg B. Ehret[18,114*]

*: contributing equally

Corresponding authors: Georg B. Ehret (georg@rhone.ch), tel. +41 22 3727200, fax +41 22 - 372 72 29, Louise V. Wain (louisewain@le.ac.uk), tel. +44 116 229 7252, fax +44 116 229 7250

AFFILIATIONS

1. Department of Health Sciences, University of Leicester, Leicester LE1 7RH, UK

2. Department of Epidemiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands

3. Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

4. Department of Psychiatry, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands

5. Hebrew SeniorLife, Harvard Medical School, 1200 Centre Street Room #609, Boston, MA 02131, USA

6. National Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, MA 01702, USA

7. Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK

8. Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK

9. NIHR Barts Cardiovascular Biomedical Research Unit, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK

10. Division of Preventive Medicine, Brigham and Women's Hospital, Boston MA 02215, USA

11. Department of Epidemiology, Erasmus MC, Rotterdam, 3000CA, The Netherlands

12. Department of Biological Psychology, Vrije Universiteit, Amsterdam, EMGO+ institute, VU University medical center, Amsterdam, The Netherlands

13. Cardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, 17176, Sweden

14. Centre for Molecular Medicine, Karolinska Universitetsjukhuset, Solna, 171 76, Sweden

15. Estonian Genome Center, University of Tartu, Tartu, 51010, Estonia

16. Divisions of Endocrinology/Children's Hospital, Boston, MA 02115, USA

17. Broad Institute of Harvard and MIT, Cambridge, MA 02139 USA

18. Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

19. The Population Science Branch, Division of Intramural Research, National Heart Lung and Blood Institute national Institute of Health, Bethesda, MD 20892, USA

20. The Framingham Heart Study, Framingham MA 01702, USA

21. The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, LABioMed at Harbor-UCLA Medical Center, 1124 W. Carson Street, Torrance, CA 90502, USA

22. Institute of Social and Preventive Medicine, Lausanne University Hospital, Route de la Corniche 10, 1010 Lausanne, Switzerland

23. Swiss Institute of Bioinformatics, Lausanne, Switzerland

24. Department of Cardiology, Leiden University Medical Center, Leiden, 2300RC, The Netherlands

25. Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, 2300RC, The Netherlands

26. Institute for Community Medicine, University Medicine Greifswald, Greifswald, 17475, Germany

27. DZHK (German Centre for Cardiovascular Research), partner site Greifswald, Greifswald, 17475, Germany

28. Institute of Epidemiology II, Helmholtz Zentrum München, Neuherberg 85764, Germany

29. Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA 98101, USA

30. Icelandic Heart Assoication, Kopavogur, Iceland

31. Faculty of Medicine, University of Iceland, Reykjavik, Iceland

32. Genetic Epidemiology Unit, Department of Epidemiology, Erasmus MC, Rotterdam, 3000CA, The Netherlands

33. Department of Clinical Chemistry, Fimlab Laboratories, Tampere 33520, Finland

34. Department of Clinical Chemistry, Faculty of Medicine and Life Sciences, University of Tampere, Tampere 33014, Finland

35. Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK

36. MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK

37. Clinical Division of Neurogeriatrics, Department of Neurology, Medical University Graz, Auenbruggerplatz 22, 8036 Graz, Austria

38. Institute of Medical Informatics, Statistics and Documentation, Medical University Graz, Auenbruggerplatz 2, 8036 Graz, Austria

39. Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh EH89AG, Scotland, UK

40. Department of Health, National Institute for Health and Welfare (THL), Helsinki, Finland

41.   Division of Genetics and Cell Biology, San Raffaele Scientific Institute, 20132 Milano, Italy

42.   Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DU, UK

43.   Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, 20892, USA

44.   Data Tecnica International, Glen Echo, MD, USA

45.   Human Molecular Genetics Research Group, Institute of Molecular and Cell Biology, University of Tartu, Riia St.23, 51010 Tartu, Estonia

46.   Medical Genetics, IRCCS-Burlo Garofolo Children Hospital, Via dell'Istria 65, Trieste, Italy

47.   Department of Medical, Surgical and Health Sciences, University of Trieste, Strada di Fiume 447, Trieste, 34100, Italy

48.   Institute for Biomedicine, Eurac Research, Affiliated Institute of the University of Lübeck, Bolzano, Italy

49.   Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

50.   Cardiovascular Epidemiology and Genetics, IMIM. Dr Aiguader 88, Barcelona, 08003, Spain

51.   Institute of Genetics and Biophysics A. Buzzati-Traverso, CNR, via P. Castellino 111, 80131 Napoli, Italy

52.   Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ, UK

53.   Department of Psychiatry, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland

54.   University College Dublin, UCD Conway Institute, Centre for Proteome Research, UCD, Belfield, Dublin, Ireland

55.   Department of Immunology, Genetics and Pathology, Uppsala Universitet, Science for Life Laboratory, Husargatan 3, Uppsala, SE-75108, Sweden

56.   Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI 48109, USA

57.   Department of Cardiovascular Sciences, University of Leicester, Leicester LE3 9QP, UK

58.   NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester LE3 9QP, UK

59.   MRC Human Genetics Unit, IGMM, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU Scotland, UK

60.   Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London W2 1PG, United Kingdom

61.   Department of Cardiology, Ealing Hospital, London North West Healthcare NHS Trust, Uxbridge Rd, Southall UB1 3HW, UK

62.   MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK

63.   Medical Genetics Section, University of Edinburgh Centre for Genomic and Experimental Medicine and MRC Institute of Genetics and Molecular Medicine, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK

64.   Department of Medical Biology, Faculty of Medicine, University of Split, Croatia

65.   The Charles Bronfman Institute for Personalized Medicine, Icachn School of Medicine at Mount Sinai, New York, NY 10029, USA

66.   Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, 45110, Greece

67.   Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, Scotland, UK

68.   Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad, 22060, Pakistan

69.   Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands

70.   Department of Twin Research and Genetic Epidemiology, King's College London, Lambeth Palace Rd, London, SE1 7EH, UK

71.   National Institute for Health Research Biomedical Research Centre, London SE1 9RT, UK

72.   Department of Human Genetics, Wellcome Trust Sanger Institute, CB10 1HH, United Kingdom

73.   Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK

74.   Generation Scotland, Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK

75.   Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

76.   INSERM U 1219, Bordeaux Population Health center, Bordeaux, France

77.   Bordeaux University, Bordeaux, France

78.   Hunter Medical Research Institute, New Lambton, NSW 2305, Australia

79.   Center for Statistical Genetics, Dept. of Biostatistics, SPH II, 1420 Washington Heights, Ann Arbor, MI 48109-2029, USA

80.   Department of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Isfahan, Iran

81.   Busselton Population Medical Research Institute, Western Australia

82.   PathWest Laboratory Medicine of Western Australia, NEDLANDS, Western Australia

83.   School of Pathology and Laboratory Medicine, The University of Western Australia, NEDLANDS, Western Australia

84.   For a complete list of contributing authors, please see Supporting Information.

85.   Imperial College Healthcare NHS Trust, London, UK

86.   Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA

87.   University of Dundee, Ninewells Hospital & Medical School, Dundee, DD1 9SY, UK

88.   Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK

89. Department of Pathology, Amsterdam Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

90. Department of Psychology, University of Edinburgh, 7 George Square, Edinburgh, EH8 9JZ, UK

91. Department of Molecular Epidemiology, Leiden University Medical Center, Leiden, 2300RC, The Netherlands

92. Center for Information Technology, NIH, USA

93. Department of Internal Medicine B, University Medicine Greifswald, Greifswald, 17475, Germany

94. Department of Numerical Analysis and Computer Science, Stockholm University, Lindstedtsvägen 3, Stockholm, 100 44, Sweden

95. Department of Public Health and Caring Sciences, Geriatrics, Uppsala 752 37, Sweden

96. Helmholtz Zentrum Muenchen, Deutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbH), Ingolstaedter Landstr. 1, 85764 Neuherberg, München, Germany

97. Department of Psychology, School of Social Sciences, Heriot-Watt University, Edinburgh, EH14 4AS, UK

98. Intramural Research Program, Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, USA

99. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

100. School of Population and Global Health, The University of Western Australia, NEDLANDS, Western Australia

101. Center For Life-course Health Research, P.O. Box 5000, FI-90014 University of Oulu, Finland

102. Biocenter Oulu, P.O. Box 5000, Aapistie 5A, FI-90014 University of Oulu, Finland

103. Unit of Primary Care, Oulu University Hospital, Kajaanintie 50, P.O. Box 20, FI-90220 Oulu, 90029 OYS, Finland

104. MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, W2 1PG London, UK

105. National Heart, Lung and Blood Institute, Cardiovascular Epidemiology and Human Genomics Branch, Bethesda, MD 20814, USA

106. Department of Clinical Physiology, Tampere University Hospital, Tampere 33521, Finland

107. Department of Clinical Physiology, Faculty of Medicine and Life Sciences, University of Tampere, Tampere 33014, Finland

108. Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA 02114, USA

109. Center for Human Genetics, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA

110. Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA

111. Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge CB2 2SR, UK

112. Department of Public Health, Faculty of Medicine, University of Split, Croatia

113. See complete listing of contributors in the Supporting Information.

114. Cardiology, Department of Medicine, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva 14, Switzerland

115. Department of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Uppsala 751 85, Sweden

116. Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK

117. Department of Psychiatry, EMGO Institute for Health and Care Research, VU University Medical Center, A.J. Ernststraat 1187, 1081 HL Amsterdam, The Netherlands

118. School of Molecular, Genetic and Population Health Sciences, University of Edinburgh, Medical School,Teviot Place, Edinburgh, EH8 9AG, Scotland, UK

119. Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, University of Texas Health Science Center at Houston, 1200 Pressler St., Suite 453E, Houston, TX 77030, USA

120. Interdisciplinary Center Psychopathology and Emotion Regulation (IPCE), University of Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30001, 9700 RB Groningen, The Netherlands

121. British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK

122. Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland

123. Department of Pathology and Molecular Medicine, McMaster University, 1280 Main St W, Hamilton, L8S 4L8, Canada

124. School of Public Health, Imperial College London, W2 1PG, UK

125. Department of Neurology, General Central Hospital, Bolzano, Italy

126. Department of Neurology, University of Lübeck, Lübeck, Germany

127. Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku 20521, Finland

128. Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku 20014, Finland

129. Department of Cardiology, Fujian Provincial Hospital, Fujian Medical University, Fuzhou 350001, China

130. Department of Biostatistics University of Washington, Seattle, WA 98101, USA

131. Harvard Medical School, Boston MA, USA

132. Institute for Maternal and Child Health IRCCS Burlo Garofolo, Via dell'Istria 65, Trieste, 34200, Italy

133. The Institute for Translational Genomics and Population Sciences, Departments of Pediatrics and Medicine, LABioMed at Harbor-UCLA Medical Center, 1124 W. Carson Street, Torrance, CA 90502, USA

134.   Institute of Molecular Biology and Biochemistry, Centre for Molecular Medicine, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria

135.   INSERM U1078, Etablissement Français du Sang, 46 rue Félix Le Dantec, CS 51819, Brest Cedex 2 29218, France

136.   Faculty of Health, University of Newcastle, Callaghan NSW 2308, Australia

137.   John Hunter Hospital, New Lambton NSW 2305, Australia

138.   School of Medicine, Conway Institute, University College Dublin, Ireland

139.   The New York Academy of Medicine. 1216 5th Ave, New York, NY 10029, USA

140.   IRCCS Neuromed, Pozzilli, Isernia, Italy

141.   Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland

142.   Institute of Cardiovascular and Medical Sciences, Faculty of Medicine, University of Glasgow, United Kingdom

143.   Department of Genetics, University of Groningen, University Medical Center Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands

144.   Institute for Translational Genomics and Population Sciences. Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, 90502, USA

145.   Division of Genetic Outcomes, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, 90502, USA

146.   International Centre for Circulatory Health, Imperial College London, W2 1PG, UK

147.   Department of Public Health, Bordeaux University Hospital, Bordeaux, France

148.   Department of Internal Medicine, Erasmus MC, Rotterdam, 3000CA, The Netherlands

149.   Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, 17475, Germany

150.   Department of Internal Medicine, Lausanne Universiyt Hospital, CHUV, 1011 Lausanne, Switzerland

151.   Population Health Research Institute, McMaster University, Hamilton Ontario, Canada

152.   National Heart and Lung Institute, Imperial College London, W2 1PG, UK

153.   Department of Neurology, Bordeaux University Hospital, Bordeaux, France

154.   Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands

155.   Department of Cardiology, University of Groningen, University Medical Center Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands

156.   The Charles Bronfman Institute for Personalized Medicine, The Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

157.   Mindich Child health Development Institute, The Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

158.   Alzheimer Scotland Dementia Research Centre, University of Edinburgh, 7 George Square, Edinburgh, EH8 9JZ, UK

159.   Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK

160. National Heart and Lung Institute, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK

161. Diabetes Prevention Unit, National Institute for Health and Welfare, 00271 Helsinki, Finland

162. South Ostrobothnia Central Hospital, 60220 Seinäjoki, Finland

163. Red RECAVA Grupo RD06/0014/0015, Hospital Universitario La Paz, 28046 Madrid, Spain

164. Centre for Vascular Prevention, Danube-University Krems, 3500 Krems, Austria

165. Division of Cardiovascular Sciences, The University of Manchester, Manchester, UK and Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK

166. Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila Str. 19, 50412 Tartu, Estonia

167. Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, 27106, USA

168. University of Tartu, Tartu, Estonia

169. Department of Neurology, Medical University Graz, Auenbruggerplatz 22, 8036 Graz, Austria

170. Department of Epidemiology University of Washington, Seattle, WA 98101, USA

171. Department of Health Services, University of Washington, Seattle, WA 98101, USA

172. Group Health Research Institute, Group Health, Seattle, WA, 98101, USA

173. Institute of Physiology, University Medicine Greifswald, Karlsburg, 17495, Germany

174. Department of Pulmonary Physiology and Sleep, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands 6009,H57, Western Australia

175. School of Medicine and Pharmacology, University of Western Australia, Australia

176. Population Health Research Institute, St George's, University of London, London SW17 0RE, UK

177. Department of Medicine, Columbia University Medical Center, 622 West 168th Street, PH 9, East, 107, New York, NY 10032, USA

178. Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala 752 37, Sweden

179. Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA

180. Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA

181. Data Science Institute and Lancaster Medical School, Lancaster University, LA1 4YG, UK

182. Department of Biostatistics, University of Liverpool, Block F, Waterhouse Building, 1-5 Brownlow Street, Liverpool L69 3GL, UK

183. The population Science Branch, Division of Intramural Research, National Heart Lung and Blood Institute national Institute of Health, Bethesda MD 20892, USA

Corresponding authors: Louise V. Wain (louisewain@le.ac.uk) and Georg B. Ehret (georg@jhmi.edu)

ABSTRACT

Elevated blood pressure is a major risk factor for cardiovascular disease and has a substantial genetic contribution. Genetic variation influencing blood pressure has the potential to identify new pharmacological targets for the treatment of hypertension. To discover additional novel blood pressure loci, we used 1000 Genomes Project-based imputation in 150,134 European ancestry individuals and sought significant evidence for independent replication in a further 228,245 individuals. We report 6 new signals of association in or near *HSPB7*, *TNXB*, *LRP12*, *LOC283335*, *SEPT9* and *AKT2*, and provide new replication evidence for a further 2 signals in *EBF2* and *NFKBIA*. Combining large whole-blood gene expression resources totaling 12,607 individuals, we investigated all novel and previously reported signals and identified 48 genes with evidence for involvement in BP regulation that are significant in multiple resources. Three novel kidney-specific signals were also detected. These robustly implicated genes may provide new leads for therapeutic innovation.

INTRODUCTION

Genetic support for a drug target increases the likelihood of success in drug development [1] and there is clear unmet need for novel therapeutic strategies to treat individuals with hypertension [2]. A number of large studies have described blood pressure (BP) variant identification by genome-wide and targeted association approaches [3-19]. Clinically the most predictive BP traits for cardiovascular risk are systolic blood pressure (SBP) and diastolic blood pressure (DBP), reflecting roughly the peak and trough of the BP curve, and pulse pressure (PP), the difference between SBP and DBP [20] reflecting arterial stiffness. Using these three traits, we undertook a meta-analysis of 150,134 individuals from 54 genome-wide association studies of European ancestry with imputation based on the 1000 Genomes Project Phase 1. To minimize reporting of false positive associations, we sought stringent evidence for significant independent replication in a further 228,245 individuals. We further followed up novel and previously reported association signals in multiple large gene expression databases and the largest kidney tissue gene expression resource currently available. Finally, we searched for enrichment of associated genes in biological pathways and gene sets and identified whether any of the genes were known drug targets or had tool molecules.

MATERIALS AND METHODS

Studies Stage 1

Results from 54 independent European-ancestry studies, totaling 150,134 individuals, were included in the Stage 1 meta-analysis: AGES (n=3215), ARIC (n=9402), ASPS (n=828), B58C (n=6458), BHS (n=4492), CHS (n=3254), Cilento study (n=999), COLAUS (n=5404), COROGENE-CTRL (n=1878), CROATIA-Vis (n=945), CROATIA-Split (n=494), CROATIA-Korcula (n=867), EGCUT (n=6395), EGCUT2 (n=1844), EPIC (n=2100), ERF (n=2617), Fenland (n=1357), FHS (n=8096), FINRISK-ctrl (n=861), FINRISK CASE (n=839), FUSION (n=1045), GRAPHIC (n=1010), H2000-CTRL (n=1078), HealthABC (n=1661), HTO (n=1000), INGI-CARL (n=456), INGI-FVG (n=746), INGI-VB (n=1775), IPM (n=300), KORAS3 (n=1590), KORAS4 (n=3748), LBC1921 (n=376), LBC1936 (n=800), LOLIPOP-EW610 (n=927), MESA (n=2678), MICROS (n=1148), MIGEN (n=1214), NESDA (n=2336), NSPHS (n=1005), NTR (n=1490), PHASE (n=4535), PIVUS (n=945), PROCARDIS (n=1652), SHIP (n=4068), ULSAM (n=1114), WGHS (n=23049), YFS (n=1987), ORCADES (n=1908), RS1 (n=5645), RS2 (n=2152), RS3 (n=3018), TRAILS (n=1262), TRAILS-CC (n=282) and TWINGENE (n=9789). Full study names and general study information is given in **Supplementary Table 1**.

Study-level genotyping and association testing

Three quantitative BP traits were analyzed: SBP, DBP, and PP (difference between SBP and DBP). Within each study, individuals known to be taking anti-hypertensive medication had 15 mmHg added to their raw SBP value and 10 mmHg added to their raw DBP values [21]. A summary of BP phenotypes in each study is given in **Supplementary Table 2**. Association testing was undertaken according to a central analysis plan that specified the use of sex,

age, age^2, and body mass index (BMI) as covariates and optional inclusion of additional covariates to account for population stratification (**Supplementary Table 3**). Trait residuals were calculated for each trait using a normal linear regression of the medication-adjusted trait values (mmHg) onto all covariates. The genotyping array, pre-imputation quality control filters, imputation software and association testing software used by each study are listed in **Supplementary Table 4.** All studies imputed to the 1000 Genomes Project Phase 1 integrated release version 3 [March 2012] all ancestry reference panel [22]. Imputed genotype dosages were used to take into account uncertainty in the imputation. Association testing was carried out using linear regression of the trait residuals onto genotype dosages under an additive genetic model. Methods to account for relatedness within a study were used where appropriate (**Supplementary Table 3**). Results for all variants (SNPs and INDELs) were then returned to the central analysis group for further quality control checks and meta-analysis.

Stage 1 meta-analysis

Central quality control checks were undertaken across all results sets. This included checks to ensure allele frequency consistency (across studies and with reference populations), checks of effect size and standard error distributions (i.e. to highlight phenotype issues) and generation of quantile-quantile (QQ) plots and genomic inflation factor lambdas to check for over- or under-inflation of test statistics. Genomic control was applied (if lambda>1) at study-level. Variants with imputation quality <0.3 were excluded prior to meta-analysis. Inverse variance weighted meta-analysis was undertaken. After meta-analysis, variants with a weighted minor allele frequency of less than 1% or N effective (product of study sample

size and imputation quality summed across contributing studies) <60% were then excluded and meta-analysis genomic control lambda calculated and used to adjust the meta-analysis results.

Selection of regions for follow-up

For each trait, regions of association were selected by ranking variants by *P* value, recording the variant with the lowest *P* value as a sentinel variant and then excluding all variants +/- 500kb from the sentinel and re-ranking the remaining variants. This was undertaken iteratively until all sentinel variants representing 1Mb regions containing associations with *P* < 10^{-6} had been identified. To identify additional signals represented by secondary sentinel variants within 500kb of each of the sentinel variants, GCTA [23] was used to run conditional analyses (conditioned on the first sentinel variant) on each of the 1Mb regions using GWAS summary statistics and LD information from ARIC. This was done both for putatively novel regions and for regions that had previously been reported. A chi-squared test of heterogeneity of effect sizes across the 54 studies was run for each sentinel variant and those with *P* < 0.05 for heterogeneity were excluded from further follow-up. Variants with *P* <10^{-6} after conditioning on the sentinel SNP (novel or known) in the region and for which any attenuation of the −log10 *P* value was less than 1.5 fold, were also taken forward for replication.

Studies stage 2

Data from 14 independent studies, totaling 87,360 individuals, and the first release of UK Biobank, totaling 140,886 individuals, were combined to replicate the findings from stage 1

(i.e. totaling 228,245 individuals). Stage 2 study details, including full study names, are given in **Supplementary Table 6** and included 3C-Dijon (n=4061), Airwave (n=14023), ASCOT-SC (n=2462), ASCOT-UK (n=3803), BRIGHT (n=1791), GAPP (n=1685), GoDARTs (n=7413), GS:SFHS (n=9749), HCS (n=2112), JUPITER (n=8718), LifeLines (n=13376), NEO (n=5731), TwinsUK (n=4973), UK Biobank-CMC (n=140,886) and UKHLS (n=7462). Analysis was undertaken using the same methods as described for Stage 1 studies. UK Biobank-CMC utilized a newer imputation reference panel than the other studies and where a requested variant was not available, a proxy was used (next most significant P value with linkage disequilibrium $r^2 > 0.6$ with original top variant). Results from all stage 2 studies were meta-analyzed using inverse-variance weighted meta-analysis. Two of the variants, rs1048238 and chr1:243458005:INDEL, were not available in the largest study in Stage 2 (UK Biobank-CMC) and so proxy variants were selected (based on P value and LD).

Stage 1 + Stage 2 meta-analysis

Following meta-analysis of stage 1 and stage 2 results, signals with a $P > 5 \times 10^{-8}$ were excluded. Of the signals with a final $P < 5 \times 10^{-8}$, support for independent replication within the stage 2 studies only was sought. Any signals which had $P < 5 \times 10^{-8}$ and evidence for independent replication in stage 2 alone, indicated by $P < 8.2 \times 10^{-4}$ (Bonferroni correction for 61 tests) were reported as novel signals of association with BP. Any signals which were subsequently reported by other BP GWAS that were accepted for publication during the time this analysis was ongoing, or signals for which independence from another known signal could not be established, were removed from our list of novel signals at this stage (**Supplementary Table 5**).

Genotype and gene expression

We searched for signals of association of genotype with gene expression for the 22 signals (including 8 novel) signals described in this study (**Supplementary Table 7**) and all signals reported prior to our study (**Supplementary Table 10**) [3-16, 18, 24] in 3 whole-blood data sets, 1 kidney data set and the GTEx multiple tissue data resource, which included whole-blood [25]. We selected cis signals of association which were significant after controlling for 5% False Discovery Rate (FDR). The 3 whole-blood eQTL data sets were the NHLBI Systems Approach to Biomarker Research in Cardiovascular Disease initiative whole-blood eQTL resource (SABRe) (microarray, n=5257), NESDA-NTR (microarray, n=4896), BIOS (RNAseq, n=2116). The whole-blood data from GTEx was based on data from 338 samples. The kidney data set comprised 236 donor-kidney samples from 134 donors [26]. Full details of each data set can be found in the **Supporting Information**. The source transcriptomic renal data as described[26] have been deposited in the GeneExpression Omnibus (NCBI) and are accessible online through GEO Series accession number GSE43974.

LD lookup

The 1000 Genomes Project phase 3 release of variant calls was used (Feb. 20th, 2015), using 503 subjects of European ancestry[22]. r^2 between the sentinel SNPs and all other bi-allelic SNPs within the corresponding 2 Mb area was calculated using the Tabix and PLINK software package (v1.07) [27, 28]. Annotation was performed using the ANNOVAR software package[29].

Gene-based pathway analysis

All genes identified in 3 or 4 of the whole-blood eQTL resources above (**Table 2**), and genes containing a non-synonymous variant with $r^2 > 0.5$ with the sentinel variant (**Supplementary Table 13**), were tested for enrichment of biological pathways and gene ontology terms using ConsensusPathDB [30] using a FDR < 5% cut-off. Enriched pathways and GO terms containing genes only implicated by a single BP-associated variant were not reported.

Network analysis

To construct a functional association network, we combined two prioritized candidate gene sets into a single query gene set as (i) genes mapping to the non-synonymous SNPs (nsSNPs) in high LD ($r^2 > 0.5$) with the corresponding sentinel BP associated SNP, and (ii) genes with eQTL evidence from 3 or 4 of the blood eQTL resources. Three sentinel SNPs (rs185819, rs926552 and rs805303) mapping to the HLA region on chromosome 6 were excluded from downstream analyses. The single query gene set was then used as input for the functional network analysis[31]. We used the Cytoscape [32] software platform extended by the GeneMANIA[33] plugin (Data Version: 8/12/2014)[34]. All the genes in the composite network, either from the query or the resulting gene sets, were then used for functional enrichment analysis against Gene Ontology terms (GO terms)[35] to identify the most relevant GO terms using the same plugin [34].

DNase1 Hypersensitivity overlap enrichment across tissue and cell-types

The Functional element Overlap analysis of the Results of Genome Wide Association Study (GWAS) Experiments (Forge tool v1.1)[36] was used to test for enrichment of overlap of BP SNPs in tissues and cell lines from the Roadmap and ENCODE projects. All 164 SNPs were

entered and 143 were included in the analysis. SNPs from 9 commonly used GWAS arrays were used to select background sets of SNPs for comparison and 10,000 background repetitions were run. A Z-score threshold of >=3.39 (estimated false positive rate of 0.5%) was used to declare significance.

Drug-gene interactions

Genes used for pathway and gene ontology enrichment analyses were further investigated for potential druggable or drugged targets using the drug gene interaction database (DGIdb). Known drug-gene interactions were interrogated across 15 source databases in DGIdb and include all types of interactions. The analysis performed for druggability prediction included all 9 databases exclusively inspecting expert curated data only. We also evaluate genes for known tool compounds using Chembl (www.ebi.ac.uk/chembl/; version 22.1).

RESULTS

The stage 1 discovery meta-analysis included 150,134 individuals (**Online Methods**; **Supplementary Tables 1-4, Supplementary Figures 1** and **2**) and 7,994,604 variants with minor allele frequency (MAF) > 1% and an effective sample size of at least 60% of the total (**Online Methods**). We employed the widely used 2-stage design[37] and identified 61 signals in the discovery analysis that were candidates for novel BP signals ($P < 10^{-6}$ for any trait; **Supplementary Table 5**). To ensure robustness of signals, we examined BP associations in an additional 228,245 individuals from 15 independent studies for replication, including 140,886 individuals from UK Biobank [19] (**Supplementary Table 6** and **Online Methods**). We used the most significant ("sentinel") SNP and trait for each locus in replication (61 tests). Twenty-two putatively novel association signals were initially confirmed showing significant evidence of replication in the independent stage-2 studies ($P < 8.2 \times 10^{-4}$, Bonferroni correction for 61 tests) and genome-wide significance ($P < 5 \times 10^{-8}$) in a meta-analysis across all 378,376 individuals (**Online methods, Table 1, Supplementary Table 7**). Of these, 14 were subsequently published in two other studies [17, 19] which presented genome-wide significant associations with evidence of replication. A further two were highlighted as putative novel signals in one of those studies [17] but had not been confirmed by replication. In our study, we report the 6 remaining novel signals, and the 2 previously unconfirmed signals (in *EBF2* and in *NFKBIA*), as novel signals. The 8 novel signals included 7 signals at 7 independent loci (**Supplementary Figure 3**) and one novel independent signal near a previously reported hit near *TNXB* (**Online Methods, Supplementary Table 8, Supplementary Figure 4**). The novel signals show both significant evidence of replication in the independent stage-2 studies ($P < 8.2 \times 10^{-4}$, Bonferroni correction for 61 tests) and

genome-wide significance ($P < 5\times10^{-8}$) in a meta-analysis across all 378,376 individuals. The sentinel variants at all 8 signals were common (MAF>5%) and the novel secondary signal at *TNXB* was in high linkage-disequilibrium ($r^2 > 0.8$) with a non-synonymous SNP. With the exception of rs9710247, which was only significant for association with DBP, all signals were significantly associated (P < 0.006, Bonferroni corrected for 8 tests) with all 3 traits (**Table 1** and **Supplementary Table 9**).

We next sought to identify which genes might have expression levels that were associated with genotypes of the BP-associated variants reported in this study and others. Strong evidence of an association with expression of a specific gene may provide clues as to which gene(s) might be functionally relevant to that signal. We took the 139 BP association signals reported prior to these studies [17, 19], and 22 novel signals of association identified and confirmed in this study and two contemporaneous studies [3-19, 24] (**Supplementary Table 10**), and searched for evidence of association with gene expression in whole-blood (four studies, total n=12,607; **Online Methods**) and in kidney tissue (n=134, the largest kidney eQTL resource currently available). Although of unclear direct relevance to BP, whole-blood was studied due to the availability of large data sets enabling a powerful assessment of expression patterns that are likely present across multiple cell and tissue types. Similarly, circulating blood cells have been used for ion transport experiments in the past and altered ion transport levels in erythrocytes were linked to hypertension.[38] Kidney was chosen because of the many renal pathways that regulate BP and outstanding questions about the relevance of kidney pathways to the genetic component of BP regulation in the general population [3, 15]. Expression quantitative trait loci (eQTL) signals were filtered by false

discovery rate (FDR < 5%) and we examined *cis* (within 1Mb) associations only (**Online methods** and **Supporting Information**).

The four blood eQTL data sets were NESDA-NTR [39, 40], SABRe [15], the BIOS resource [41] and GTEx[25] (**Online Methods and Supporting Information**). The BIOS resource (n=2,116) has not previously been utilized in the analysis of BP associations, findings from NESDA-NTR and SABRe have been reported for a subset of the previously published signals [16, 18]. For a total of 369 genes, gene-expression was associated with the BP SNP in one or more of the 4 blood datasets at experiment-wide significance (**Supplementary Table 11**). This included 14 genes for 6 of the 8 novel signals. For 110 genes, we found eQTL evidence in 2 out of 4 datasets (**Figure 1**), including 4 genes for 2 of the novel signals; *EIF4B* and *TNS2* for rs73099903 and *MAP3K10* and *PLD3* for rs9710247. SNP rs73099903 was in strong linkage disequilibrium (LD r^2 > 0.9) with the SNP most strongly associated with *TNS2* expression in the BIOS resource. *TNS2* encodes a tensin focal adhesion molecule and may have a role in renal function [42].

For 48 genes, we found evidence in 3 out of the 4 resources (**Table 2**), suggesting robustness of the SNP-gene expression correlation signal and highlighting those genes as potential candidates in genetic BP regulation. Of the 48 genes, 28 have not previously been described in eQTL analyses using BP associated SNPs and all were correlated with previously reported BP association signals.

In the kidney dataset (TransplantLines) [26], there was association of gene expression and genotype for nine SNPs and 13 genes (**Table 2**, **Figure 1** and **Supplementary Table 12**). Nine

of the SNP-gene expression associations were also observed in the whole-blood eQTL

datasets, suggesting that those signals may not be unique to the kidney. We report three

signals that were unique to the kidney and not previously reported (*C4orf34*, *HIP2* and

ASIC1) and confirm a previously reported kidney eQTL signal for an anti-sense RNA for

PSMD5 [15]. The same SNP was also an eQTL for *PSMD5* itself in both blood and kidney. *ASIC1*

encodes the Acid Sensing Ion Channel Subunit 1 which may interact (and be co-expressed)

with ENaC subunits which mediate trans-epithelial Na transport in the distal nephron of the

kidney [43]. The comparatively small number of signals using kidney tissue (**Table 2** and **Figure**

1) compared to whole-blood could be due to the small sample size. Complete GTEx results

are in Supplementary Table 13.

For genes implicated by eQTL information from whole-blood, we tested for enrichment of

biological pathways and gene ontologies (**Online Methods**). We noted enrichment of the 48

genes implicated by 3 or 4 blood eQTL resources, **Table 2**, and a further 53 genes containing

a non-synonymous variant with r^2 > 0.5 with the top SNP (**Supplementary Table 14**), in

pathways and ontology terms related to actin and striated muscle (**Supplementary Tables**

15 and 16, **Online Methods**). Network analysis using the same genes highlighted further GO

terms relating to muscle function, particularly cardiac muscle (**Online Methods,**

Supplementary Table 17). We tested the overlap of 161 non-HLA BP associated variants

with DNase Hypersensitivity sites identified in the Roadmap and ENCODE cell lines (**Online**

Methods) and identified an overall enrichment in multiple cell and tissue types including

heart, kidney and smooth muscle (**Supplementary Figure 5**).

We next investigated these genes for potential suitability as drug targets (druggability), known tool compounds and clinically approved drugs using the drug gene interaction database (DGIdb) [44] (**Supplementary Table 18**). Twelve genes had known drugs, including four genes with known antihypertensive drugs. We noted that drugs modulating all but one of the 12 drugged targets had a reported influence on blood pressure, either as a primary antihypertensive indication or as a reported side effect of raised blood pressure. Twenty additional genes were predicted druggable, among these 7 genes have known small molecule tool modulators, based on a query of the Chembl database (www.ebi.ac.uk/chembldb/; version 22.1).

DISCUSSION

Enhanced discovery of BP loci increases the potential targets for therapeutic advances. After major advances in the number of BP loci known over the last years and months, we report 8 novel signals that implicate 5 regions of the genome not previously connected to blood pressure regulation.

Six of the 8 novel signals we report had not previously been reported. Two signals (in *EBF2* and *NFKBIA)* have been suggested previously but without evidence for replication [17]. For these two signals we present, for the first time, stringent evidence of replication, confirming their relevance to blood pressure genetics.

The path from signal to genes is the essential next step towards realizing the therapeutic potential of a genetic locus and understanding the mechanisms of BP regulation. We have

used several large eQTL resources as a first step to realize this objective. As expected, we observed that even across eQTL studies of the same tissue, there is limited overlap in experiment-wide significant signals suggesting either biologic variability (differences in the characteristics of the samples or in the methods for extraction and processing of mRNA in each of the studies), technology-specific differences in coverage of genes (use of RNAseq data for the BIOS blood dataset and microarray-based expression levels for the kidney and other blood datasets), or the possibility of false positive results despite stringent within-experiment significance thresholds. We were unable to distinguish these scenarios using the data available to us but by selecting genes that were significant in at least three resources, and therefore robust to these differences, we identified 48 genes as candidates for further study. These results are limited by the availability of large eQTL resources for whole-blood only, which precludes well-powered comparisons across tissue types, particularly as the origin of blood pressure control is unlikely to be located in the blood. Enrichment and pathway analyses using these genes, and genes containing a correlated functional variant, highlight the potential relevance of muscular tissue and pathways, compatible with a vascular and cardiac origin of BP genetics, extending previous evidence [15]. We identify a number of drugged targets in the pathways identified, including four existing hypertension targets. Other drugs identified are not suitable candidates for repositioning to hypertension, as most were reported in adverse events to raise blood pressure, however the targets would be valid for investigation using a reverse mechanism, e.g. agonism in place of inhibition. We also identified seven genes with small molecule tool modulators (mainly inhibitory or binding). These molecules and targets might be suitable candidates for further investigation to build a target validation case to support clinical investigation in hypertension.

Amongst the genes implicated in our eQTL analyses were several for which there is already some evidence that they are relevant to blood pressure regulation. The intronic SNP rs10926988 was independently associated with expression of *SDCCAG8* in all four whole-blood resources. Rare mutations in *SDCCAG8* cause Bardet-Biedl syndrome, which features hypertension. Expression levels of *MYBPC3* were correlated with rs7103648 [15] in the 3 largest blood eQTL resources (i.e. SABRe, NESDA-NTR and BIOS). *MYBPC3* encodes the cardiac isoform of myosin-binding protein C, which is expressed in heart muscle and mutations in *MYBPC3* are known to cause familial hypertrophic cardiomyopathy. [45]

This study has several limitations: Given the nature of statistical power for genome-wide association analyses, the sample size is limited, even though this is one of the largest efforts in BP GWAS undertaken so far. The study would clearly have benefited from the availability of larger eQTL resources on multiple tissues in sample sizes even larger than those available today. Our analyses were limited to *cis*-signals and future analyses, with larger sample sizes, might also consider trans-signals.

PERSPECTIVES

Our study reports robust novel BP association signals and reports new candidate BP genes, contributing to the transition from variants to genes to explain BP variation. These genes now require further functional validation to establish their potential as drug targets. Our study additionally highlights the challenges of combining and interpreting data from multiple eQTL studies and emphasizes the need for harmonization of data and development of new eQTL resources for multiple tissue types.

In summary, our study reports novel BP association signals and reports new candidate BP genes, contributing to the transition from variants to genes to explain BP variation.

DISCLOSURES

The authors declare competing financial interests (see corresponding section in the Supporting Information).

SOURCES OF FUNDING: See end of the manuscript.

NOTE: Online data supplements are available in the online version of the paper.

REFERENCES

1.   Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li

        MJ, Wang J, Cardon LR, Whittaker JC, Sanseau P. The support of human genetic

        evidence for approved drug indications. *Nat Genet*. 2015;47:856-860.

2.   Mancia G, Fagard R, Narkiewicz K, et al. 2013 esh/esc guidelines for the management

        of arterial hypertension: The task force for the management of arterial hypertension

        of the european society of hypertension (esh) and of the european society of

        cardiology (esc). *Eur Heart J*. 2013;34:2159-2219.

3.   Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence

        blood pressure and cardiovascular disease risk. *Nature*. 2011;478:103-109.

4.   Ganesh SK, Chasman DI, Larson MG, et al. Effects of long-term averaging of

        quantitative blood pressure traits on the detection of genetic associations. *American

        journal of human genetics*. 2014;95:49-65.

5.   Johnson AD, Newton-Cheh C, Chasman DI, et al. Association of hypertension drug

        target genes with blood pressure and hypertension in 86,588 individuals.

        Hypertension. 2011;57:903-910.

6.   Johnson T, Gaunt TR, Newhouse SJ, et al. Blood pressure loci identified with a gene-

        centric array. *The American Journal of Human Genetics*. 2011;89:1-13.

7.   Kato N, Takeuchi F, Tabara Y, et al. Meta-analysis of genome-wide association

        studies identifies common variants associated with blood pressure variation in east

        asians. *Nat Genet*. 2011;43:531-538.

8.   Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood pressure and

        hypertension. *Nat Genet*. 2009;41:677-687.

9.   Newton-Cheh C, Johnson T, Gateva V, et al. Genome-wide association study

        identifies eight loci associated with blood pressure. *Nat Genet*. 2009;41:666-676.

10.   Newton-Cheh C, Larson MG, Vasan RS, et al. Association of common variants in nppa

        and nppb with circulating natriuretic peptides and blood pressure. *Nat Genet*.

        2009;41:348-353.

11.   Padmanabhan S, Melander O, Johnson T, et al. Genome-wide association study of

        blood pressure extremes identifies variant near umod associated with hypertension.

        PLoS Genet. 2010;6:e1001177.

12.   Simino J, Shi G, Bis JC, et al. Gene-age interactions in blood pressure regulation: A

        large-scale investigation with the charge, global bpgen, and icbp consortia. *American

        journal of human genetics*. 2014;95:24-38.

13.   Tragante V, Barnes MR, Ganesh SK, et al. Gene-centric meta-analysis in 87,736

        individuals of european ancestry identifies multiple blood-pressure-related loci.

        American journal of human genetics. 2014;94:349-360.

14.   Wain LV, Verwoert GC, O'Reilly PF, et al. Genome-wide association study identifies

        six new loci influencing pulse pressure and mean arterial pressure. *Nat Genet*.

        2011;43:1005-1011.

15.   Ehret GB, Ferreira T, Chasman DI, et al. The genetics of blood pressure regulation

        and its target organs from association studies in 342,415 individuals. *Nat Genet*.

        2016;48:1171-1184.

16.   Liu C, Kraja AT, Smith JA, et al. Meta-analysis identifies common and rare variants

        influencing blood pressure and overlapping with metabolic trait loci. *Nat Genet*.

        2016;48:1162-1170.

17.   Hoffmann TJ, Ehret GB, Nandakumar P, Ranatunga D, Schaefer C, Kwok PY, Iribarren C, Chakravarti A, Risch N. Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation. *Nat Genet*. 2017;49:54-64.

18.   Surendran P, Drenos F, Young R, et al. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. *Nat Genet*. 2016;48:1151-1161.

19.   Warren HR, Evangelou E, Cabrera CP, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nat Genet*. 2017;49:403-415.

20.   Safar ME, Nilsson PM, Blacher J, Mimran A. Pulse pressure, arterial stiffness, and end-organ damage. *Curr Hypertens Rep*. 2012;14:339-344.

21.   Tobin MD, Sheehan NA, Scurrah KJ, Burton PR. Adjusting for treatment effects in studies of quantitative traits: Antihypertensive therapy and systolic blood pressure. *Stat Med*. 2005;24:2911-2935.

22.   Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA. An integrated map of genetic variation from 1,092 human genomes. *Nature*. 2012;491:56-65.

23.   Yang J, Lee SH, Goddard ME, Visscher PM. Gcta: A tool for genome-wide complex trait analysis. *American journal of human genetics*. 2011;88:76-82.

24.   Kato N, Loh M, Takeuchi F, et al. Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. *Nat Genet*. 2015;47:1282-1293.

25. Consortium GT. Human genomics. The genotype-tissue expression (gtex) pilot analysis: Multitissue gene regulation in humans. *Science*. 2015;348:648-660.

26. Damman J, Bloks VW, Daha MR, van der Most PJ, Sanjabi B, van der Vlies P, Snieder H, Ploeg RJ, Krikke C, Leuvenink HG, Seelen MA. Hypoxia and complement-and-coagulation pathways in the deceased organ donor as the major target for intervention to improve renal allograft outcome. *Transplantation*. 2015;99:1293-1300.

27. Li H. Tabix: Fast retrieval of sequence features from generic tab-delimited files. *Bioinformatics*. 2011;27:718-719.

28. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. Plink: A tool set for whole-genome association and population-based linkage analyses. *American journal of human genetics*. 2007;81:559-575.

29. Wang K, Li M, Hakonarson H. Annovar: Functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res*. 2010;38:e164.

30. Kamburov A, Stelzl U, Lehrach H, Herwig R. The consensuspathdb interaction database: 2013 update. *Nucleic Acids Res*. 2013;41:D793-800.

31. Vaez A, Jansen R, Prins BP, Hottenga JJ, de Geus EJ, Boomsma DI, Penninx BW, Nolte IM, Snieder H, Alizadeh BZ. In silico post genome-wide association studies analysis of c-reactive protein loci suggests an important role for interferons. *Circ Cardiovasc Genet*. 2015;8:487-497.

32. Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, Pico AR, Bader GD, Ideker T. A travel guide to cytoscape plugins. *Nat Methods*. 2012;9:1069-1076.

33. Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q. Genemania: A real-time multiple association network integration algorithm for predicting gene function. *Genome Biol*. 2008;9 Suppl 1:S4.

34. Montojo J, Zuberi K, Rodriguez H, Kazi F, Wright G, Donaldson SL, Morris Q, Bader GD. Genemania cytoscape plugin: Fast gene function predictions on the desktop. *Bioinformatics*. 2010;26:2927-2928.

35. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: Tool for the unification of biology. The gene ontology consortium. *Nat Genet*. 2000;25:25-29.

36. Dunham I, Kulesha E, Iotchkova V, Morganella S, Birney E. Forge : A tool to discover cell specific enrichments of gwas associated snps in regulatory regions. *BioRxiv*. 2014;10.1101/013045 .

37. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Optimal designs for two-stage genome-wide association studies. *Genet Epidemiol*. 2007;31:776-788.

38. Trevisan M, Ostrow D, Cooper R, Liu K, Sparks S, Okonek A, Stevens E, Marquardt J, Stamler J. Abnormal red blood cell ion transport and hypertension. The people's gas company study. *Hypertension*. 1983;5:363-367.

39. Wright FA, Sullivan PF, Brooks AI, et al. Heritability and genomics of gene expression in peripheral blood. *Nat Genet*. 2014;46:430-437.

40. Jansen R, Batista S, Brooks AI, et al. Sex differences in the human peripheral blood transcriptome. *BMC Genomics*. 2014;15:33.

41. Zhernakova DV, Deelen P, Vermaat M, et al. Identification of context-dependent expression quantitative trait loci in whole blood. *Nat Genet*. 2017;49:139-145.

42.   Marusugi K, Nakano K, Sasaki H, Kimura J, Yanobu-Takanashi R, Okamura T, Sasaki N. Functional validation of tensin2 sh2-ptb domain by crispr/cas9-mediated genome editing. *J Vet Med Sci*. 2016;78:1413-1420.

43.   Jeggle P, Smith ES, Stewart AP, Haerteis S, Korbmacher C, Edwardson JM. Atomic force microscopy imaging reveals the formation of asic/enac cross-clade ion channels. *Biochem Biophys Res Commun*. 2015;464:38-44.

44.   Wagner AH, Coffman AC, Ainscough BJ, Spies NC, Skidmore ZL, Campbell KM, Krysiak K, Pan D, McMichael JF, Eldred JM, Walker JR, Wilson RK, Mardis ER, Griffith M, Griffith OL. Dgidb 2.0: Mining clinically relevant drug-gene interactions. *Nucleic Acids Res*. 2016;44:D1036-1044.

45.   Carrier L, Mearini G, Stathopoulou K, Cuello F. Cardiac myosin-binding protein c (mybpc3) in cardiac pathophysiology. *Gene*. 2015;573:188-197.

NOVELTY AND SIGNIFICANCE

What is New: The root origin of hypertension and hence blood pressure variability in the population remains unclear. This study adds data to explain the genetic basis of blood pressure variability and identifies genes likely active in blood pressure regulating pathways.

What Is Relevant: The results are of relevance for scientists, clinicians, and pharmacologists interested in hypertension. The BP loci and the BP genes identified constitute new leads for the understanding of BP pathogenesis and possibly therapeutic innovation.

Summary: Using 1000 Genomes Project-based imputation in 150,134 European ancestry and independent replication in a further 228,245 individuals we contribute 8 replicated blood pressure loci to the collection of loci currently known. Using these and previous data, 48 BP genes are identified for priority follow-up.

FIGURE LEGENDS

Figure 1: Overlap of eQTL evidence from four whole-blood and one kidney resource

The figure indicates overlap of evidence for eQTLs from four whole-blood studies (SABRe, NESDA-NTR, BIOS, and GTEx) and from one kidney resource (TransplantLines). Every colored line indicates that this gene was analysis-wide significant in a given resource (see **Online Methods**). Only genes identified by at least two resources are shown. The genes are sorted by genomic position on the y-axis.

Table 1. Novel genome-wide significant signals of association

Results from stage 1 and stage 2, and the meta-analysis of stage 1 and stage 2, for all novel genome-wide significant signals of association. *P*

values of association for all 3 traits from a meta-analysis of stages 1 and 2 are also presented. Genome-wide significant *P* values ($P<5\times10^{-8}$) are

in bold. Abbreviations: CAF: coded allele frequency se: standard error, Neff: effective sample size. #Novel signal at previously reported locus.

[1]For intragenic variants the nearest genes are listed, all other variants are intronic unless indicated otherwise; ns= non-synonymous,

s=synonymous, UTR= Untranslated Region. Results from proxy SNPs are indicated by **(proxy)**; rs848309 was a proxy SNP for rs1048238 and

rs10926988 was a proxy SNP for chr1:243458005:INDEL.

Variant ID (noncoded/coded allele) chr:position, Nearest gene(s)(type[1])	CAF	Results for most significant trait									Stage 1 + stage 2 meta-analysis P values for all traits		
		Stage 1		Stage 2			Stage 1+ stage 2						
		Beta (se)	P value	Neff	Beta (se)	P value	Neff	Beta (se)	P value	Neff	SBP	DBP	PP
SBP													
rs1048238 (C/T) 1:16341649, *HSPB7* (3'UTR)	0.571	0.366 (0.074)	8.09E-07	140299	NA	NA	NA	NA	NA	NA	NA	NA	NA
rs848309**(proxy)** (T/C) 1:16308447	0.567	0.347 (0.072)	1.70E-06	146755	0.347 (0.071)	9.10E-07	140462	0.347 (0.051)	**7.07E-12**	287217	**7.07E-12**	**1.07E-10**	5.48E-06
#rs185819 (T/C) 6:32,050,067, *TNXB* (ns)	0.513	0.534 (0.073)	1.93E-13	142397	0.277 (0.053)	1.49E-07	221748	0.365 (0.043)	**1.04E-17**	364144	**1.04E-17**	**2.24E-11**	**8.50E-15**
rs6557876 (C/T) 8:25,900,675, *EBF2*	0.252	-0.411 (0.084)	8.50E-07	143653	-0.350 (0.060)	5.66E-09	225803	-0.371 (0.049)	**2.85E-14**	369457	**2.85E-14**	**2.50E-10**	**1.51E-08**

Variant ID (noncoded/coded allele) chr:position, Nearest gene(s)(type[1])	CAF	Results for most significant trait									Stage 1 + stage 2 meta-analysis P values for all traits		
		Stage 1		Stage 2			Stage 1+ stage 2				SBP	DBP	PP
		Beta (se)	P value	Neff	Beta (se)	P value	Neff	Beta (se)	P value	Neff			
					)								
rs35783704 (G/A) 8:105,966,258, *LRP12/ZFPM2*	0.109	-0.609 (0.121)	4.96E-07	133924	-0.310 (0.089)	4.78E-04	215528	-0.414 (0.072)	**7.08E-09**	349452	**7.08E-09**	1.60E-06	2.92E-07
rs73099903 (C/T) 12:53,440,779, *LOC283335*	0.074	0.768 (0.143)	8.05E-08	136064	0.396 (0.098)	5.32E-05	207253	0.515 (0.081)	**1.95E-10**	343318	**1.95E-10**	4.53E-06	5.46E-08
rs8904 (G/A) 14:35,871,217, *NFKBIA* (3' UTR)	0.375	0.377 (0.076)	6.76E-07	140424	0.278 (0.054)	2.31E-07	224771	0.311 (0.044)	**1.31E-12**	365195	**1.31E-12**	1.13E-04	**3.44E-12**
rs57927100 (C/G) 17:75,317,300, *SEPT9*	0.258	-0.489 (0.086)	1.10E-08	136624	-0.220 (0.061)	3.12E-04	210563	-0.310 (0.050)	**4.04E-10**	347188	**4.04E-10**	**1.16E-10**	1.81E-05
DBP													
rs9710247 (A/G) 19:40,760,449, *AKT2*	0.447	0.252 (0.051)	8.11E-07	109695	0.129 (0.032)	5.76E-05	198332	0.164 (0.027)	**1.61E-09**	308028	3.82E-02	**1.61E-09**	5.03E-01

Table 2: BP associated SNPs associated with expression of the same gene across 4 or 3 independent whole-blood eQTL resources and the kidney resource. Signals of association of SNP genotype and gene expression in other non-blood tissues in GTEx and in kidney are also indicated. Blood dataset order: (i) SABRe, (ii) NESDA-NTR, (iii) BIOS, (iv) GTEx (whole-blood). Top eQTL: Top GWAS SNP is top eQTL SNP (or in high LD, r^2>0.9, with top eQTL SNP) in at least one data set. eQTL signal previously reported: Genes for which eQTL signals have been previously reported for that sentinel SNP[15, 16, 18]. For full list, see **Supplementary Table 12**.

Sentinel SNP	Chr	Position	Gene	Blood data sets	Top eQTL	Signal in other tissue(s) in GTEx	Signal in kidney	eQTL signal previously reported
Signal in 4 whole-blood eQTL resources								
rs17367504	1	11862778	CLCN6	YYYY		Y		Y
rs2169137	1	204497913	MDM4	YYYY	Y	Y		Y
rs10926988	1	243483279	SDCCAG8	YYYY		Y		
rs319690	3	47927484	MAP4	YYYY	Y	Y		Y
rs12521868	5	131784393	SLC22A5	YYYY		Y		
rs900145	11	13293905	ARNTL	YYYY		Y		Y
rs1060105	12	123806219	CDK2AP1	YYYY	Y	Y	Y	
rs1378942	15	75077367	SCAMP2	YYYY				
rs1126464	16	89704365	CHMP1A	YYYY		Y		Y
rs1126464	16	89704365	FANCA	YYYY				Y
rs12946454	17	43208121	DCAKD	YYYY		Y	Y	Y
Signal in 3 (out of 4) whole-blood eQTL resources								
rs17367504	1	11862778	MTHFR	YYYN		Y		Y
rs871524	1	38411445	FHL3	NYYY		Y		
rs871524	1	38411445	SF3A3	NYYY		Y		
rs4660293	1	40028180	PABPC4	YYYN	Y	Y		Y
rs6749447	2	169041386	STK39	YYYN	Y			

rs347591	3	11290122	ATG7	YYYN		Y		
rs319690	3	47927484	ZNF589	YYNY		Y		
rs12521868	5	131784393	SLC22A4	YYYN		Y		
rs1563788	6	43308363	CRIP3	YYYN	Y			Y
rs10943605	6	79655477	PHIP	YYYN	Y	Y		Y
rs4728142	7	128573967	IRF5	NYYY		Y	Y	Y
rs4728142	7	128573967	TNPO3	YYYN			Y	
rs2898290	8	11433909	BLK	YYYN		Y		
rs2898290	8	11433909	FAM167A	NYYY		Y		
rs2898290	8	11433909	FDFT1	YYYN		Y		
rs2071518	8	120435812	NOV	YYYN		Y		
rs76452347	9	35906471	TPM2	YYYN				
rs10760117	9	123586737	MEGF9	YYYN		Y		Y
rs4494250	10	96563757	HELLS	YYYN				Y
rs11191548	10	104846178	NT5C2	YYYN	Y			
rs661348	11	1905292	TNNT3	NYYY		Y		
rs2649044	11	9763969	SBF2	YYYN				
rs2649044	11	9763969	SWAP70	YYYN	Y	Y		?
rs7129220	11	10350538	ADM	YYYN				Y
rs7103648	11	47461783	MYBPC3	YYYN				
rs3741378	11	65408937	CTSW	YYYN				
rs7302981	12	50537815	LIMA1	YYYN				Y
rs7302981	12	50537815	ATF1	YYNY		Y		
rs1036477	15	48914926	FBN1	YNYY				
rs1378942	15	75077367	CSK	YYYN	Y	Y		Y
rs1378942	15	75077367	MPI	NYYY		Y		
rs1378942	15	75077367	ULK3	YNYY		Y		Y
rs12946454	17	43208121	NMT1	YYYN				Y
rs2304130	19	19789528	GATAD2A	YYYN				
rs867186	20	33764554	EIF6	NYYY		Y		
rs6095241	20	47308798	PREX1	YYYN				
rs9306160	21	45107562	RRP1B	YNYY	Y	Y		

CONTRIBUTIONS / ACKNOWLEDGMENTS

AUTHOR CONTRIBUTIONS

Secondary analyses

Design of secondary analyses: L.V.W., G.B.E, M.J.C., H.Snieder, M.D.T , R.Joehanes, A.V., R.Jansen, A.V., J.K., P.O.R., A.P.M., C.P.C. Computation of secondary analysis: L.V.W., G.B.E., A.P.M., M.E., T.B., L.Lin, R.Joehanes, A.V., P.J.v.d.M., R.Jansen, C.P.C.

Discovery

WGHS : Study phenotyping: P.M.R. Genotyping or analysis: D.I.C., L.M.R. Study PI: D.I.C., P.M.R.

RS : Study phenotyping: G.C.V. Genotyping or analysis: G.C.V., A.G.U. Study PI: O.H.F., A.Hofman, A.G.U.

NTR : Study phenotyping: E.J.d.G., G.W. Genotyping or analysis: J.J.H., E.J.d.G., G.W. Study PI: D.I.B., E.J.d.G.

STR : Study phenotyping: E.I. Genotyping or analysis: R.J.S., M.Frånberg Study PI: E.I., A.Hamsten

EGCUT : Genotyping or analysis: T.E. Study PI: A.Metspalu

ARIC : Genotyping or analysis: D.E.A., A.C.M., P.N. Study PI: A.Chakravarti

FHS : Study phenotyping: D.L. Genotyping or analysis: S.J.H. Study PI: D.L.

MESA : Study phenotyping: J.I.R. Genotyping or analysis: W.P., X.G., J.I.R., J.Y. Study PI: W.P.

B58C : Study phenotyping: D.P.S. Genotyping or analysis: D.P.S. Study PI: D.P.S.

COLAUS : Study phenotyping: P.V. Genotyping or analysis: M.Bochud, Z.K. Study PI: P.V.

PROSPER : Study phenotyping: J.W.J., D.J.S. Genotyping or analysis: S.Trompet, J.D. Study PI: J.W.J.

BHS : Study phenotyping: A.James Genotyping or analysis: N.Shrine, J.H., J.B.

SHIP : Study phenotyping: M.D. Genotyping or analysis: A.T., M.D., U.V. Study PI: R.R.

KORA S4 : Genotyping or analysis: J.S.R. Study PI: A.Peters

CHS : Study phenotyping: B.M.P. Genotyping or analysis: J.C.B., K.R., K.D.T. Study PI: B.M.P.

AGES-Reykjavik : Genotyping or analysis: A.V.S. Study PI: V.Gudnason, T.B.H., L.J.L.

ERF : Study phenotyping: C.M.v.D., B.A.O. Genotyping or analysis: N.A. Study PI: C.M.v.D., B.A.O.

NESDA : Study phenotyping: B.W.J.H.P. Genotyping or analysis: I.M.N., Y.M. Study PI: H.Snieder, B.W.J.H.P.

YFS : Study phenotyping: T.L., M.K., O.T.R. Genotyping or analysis: T.L., L.P.L., M.K., O.T.R. Study PI: T.L., M.K., O.T.R.

EPIC : Genotyping or analysis: N.J.W. Study PI: J.H.Z.

ASPS : Study phenotyping: R.Schmidt Genotyping or analysis: H.Schmidt, E.H., Y.S., R.Schmidt Study PI: H.Schmidt, R.Schmidt

ORCADES : Study phenotyping: J.F.W., H.C., S.W. Genotyping or analysis: J.F.W., P.K.J., S.W. Study PI: J.F.W.

FINRISK (COROGENE_CTRL) : Study phenotyping: P.J. Genotyping or analysis: K.K., A.P.S. Study PI: M.P., P.J.

INGI-VB : Study phenotyping: C.F.S. Genotyping or analysis: M.T., C.M.B., C.F.S. Study PI: D.T.

FINRISK_PREDICT_CVD : Study phenotyping: V.S., A.S.H. Study PI: V.S., A.Palotie, S.R.

TRAILS : Study phenotyping: H.R. Genotyping or analysis: P.J.v.d.M. Study PI: C.A.H., A.J.O.

PROCARDIS : Study phenotyping: A.G. Genotyping or analysis: A.G. Study PI: H.W., M.Farrall

HABC : Study phenotyping: Y.Liu, T.B.H. Genotyping or analysis: M.A.N. Study PI: Y.Liu, T.B.H.

KORA S3 : Study phenotyping: C.G. Genotyping or analysis: S.S., C.G., E.O. Study PI: M.Laan

INGI-FVG : Genotyping or analysis: D.V., M.Brumat, M.Cocca Study PI: P.G.

Fenland : Study phenotyping: R.A.S., J.a.L., C.L., N.J.W. Genotyping or analysis: R.A.S., J.a.L., C.L., N.J.W. Study PI: R.A.S., C.L., N.J.W.

MICROS : Genotyping or analysis: A.A.H., F.D.G.M., A.S.P. Study PI: F.D.G.M., P.P.P.

HTO : Study phenotyping: B.D.K. Genotyping or analysis: B.D.K., K.L.A., C.Mamasoula Study PI: B.D.K., H.J.C.

MIGEN : Study phenotyping: R.E., J.Marrugat, S.Kathiresan, D.S. Genotyping or analysis: R.E., S.Kathiresan, D.S. Study PI: S.Kathiresan

ULSAM : Study phenotyping: V.Giedraitis, E.I. Genotyping or analysis: A.P.M., A.Mahajan Study PI: A.P.M., V.Giedraitis, E.I.

Cilento study : Study phenotyping: R.Sorice Genotyping or analysis: D.R., T.Nutile Study PI: M.Ciullo

LBC1936 : Study phenotyping: I.J.D., A.J.G. Genotyping or analysis: L.M.L., G.D., A.J.G. Study PI: I.J.D.

H2000_CTRL : Study phenotyping: T.Niiranen Study PI: P.K., A.Jula, S.Koskinen

NSPHS : Genotyping or analysis: S.E., Å.J. Study PI: U.G.

FUSION : Genotyping or analysis: A.U.J. Study PI: J.T., M.Boehnke, F.C.

GRAPHIC : Study phenotyping: N.J.S., P.S.B., M.D.T. Genotyping or analysis: C.P.N., P.S.B., M.D.T. Study PI: N.J.S.

CROATIA_Vis : Study phenotyping: I.R. Genotyping or analysis: V.V., J.E.H. Study PI: V.V., I.R.

PIVUS : Study phenotyping: L.Lind, J.S. Genotyping or analysis: C.M.L., A.Mahajan Study PI: C.M.L., L.Lind, J.S.

LOLIPOP : Study phenotyping: J.S.K., J.C.C. Genotyping or analysis: J.S.K., W.Z., J.C.C., B.L. Study PI: J.S.K., J.C.C.

CROATIA_Korcula : Genotyping or analysis: C.H., J.Marten Study PI: C.H., A.F.W.

INGI-CARL : Study phenotyping: G.G. Genotyping or analysis: I.G., A.Morgan, A.R.

LBC1921 : Study phenotyping: J.M.S., A.Pattie Genotyping or analysis: J.M.S., S.E.H., D.C.M.L., A.Pattie Study PI: J.M.S.

CROATIA_SPLIT : Study phenotyping: O.P., I.K. Genotyping or analysis: O.P., T.Z. Study PI: O.P.

BioMe (formerly IPM) : Genotyping or analysis: Y.Lu Study PI: R.J.F.L., E.P.B.

Replication

UKB-BP : Genotyping or analysis: H.R.W., M.R.B., C.P.C., E.E., H.G., B.M., M.R., I.T. Study PI: P.E., M.J.C.

GoDARTS : Study phenotyping: C.N.A.P., A.S.F.D. Genotyping or analysis: C.N.A.P., N.Shah Study PI: C.N.A.P., A.D.M.

Lifelines : Study phenotyping: M.H.d.B. Genotyping or analysis: M.S. Study PI: P.v.d.H.

TwinsUK : Study phenotyping: C.Menni Genotyping or analysis: M.M., C.Menni Study PI: T.D.S.

Airwave Health Monitoring Study : Genotyping or analysis: A.C.V., E.E., H.G., I.T. Study PI: E.E.

The UK Household Longitudinal Study (UKHLS) : Genotyping or analysis: B.P.P. Study PI: E.Z.

Generation Scotland (GS:SFHS) : Study phenotyping: S.P. Genotyping or analysis: C.H., A.Campbell

JUPITER : Study phenotyping: P.M.R. Genotyping or analysis: D.I.C., L.M.R., F.G., P.M.R. Study PI: D.I.C., P.M.R.

NEO : Study phenotyping: R.d.M. Genotyping or analysis: D.O.M.K., R.L.G. Study PI: R.d.M.

Three City-Dijon : Study phenotyping: S.D., C.T. Genotyping or analysis: G.C. Study PI: S.D., C.T.

ASCOT-UK : Study phenotyping: P.S., N.P. Genotyping or analysis: P.B.M., H.R.W. Study PI: P.B.M., P.S., N.P., M.J.C.

ASCOT-SC : Study phenotyping: S.Thom, M.J.C. Genotyping or analysis: D.C.S., A.S., H.R.W., P.B.M. Study PI: S.Thom, M.J.C., P.B.M.

Hunter Community Study : Study phenotyping: R.Scott Genotyping or analysis: C.O., E.G.H. Study PI: A.John

GAPP : Study phenotyping: D.C. Genotyping or analysis: D.C., S.Thériault, G.P. Study PI: D.C.

BRIGHT : Study phenotyping: M.Brown, J.C. Genotyping or analysis: M.Farrall, P.B.M., H.R.W. Study PI: M.Brown, J.C., M.Farrall, P.B.M., M.J.C.

Resources for secondary analyses

eQTL NESDA NTR : Design of secondary analysis: R.Jansen Computation of secondary analysis: D.I.B., R.Jansen, B.W.J.H.P. Study PI: D.I.B., B.W.J.H.P.

eQTL kidney : Study phenotyping: J.J.D., M.A.S. Genotyping or analysis: P.J.v.d.M. Study PI: H.Snieder

eQTL BIOS : Design of secondary analysis: R.Jansen Computation of secondary analysis: R.Jansen Study PI: R.Jansen

SABRe : Study phenotyping: Y.D., P.J.M., Q.T.N. Genotyping or analysis: R.Joehanes Design of secondary analysis: D.L. Study PI: D.L.

ICBP-Steering Committee

participants, and to the whole team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses.

INGI-VB: The INGI-Val Borbera population is a collection of 1,664 genotyped samples collected in the Val Borbera Valley, a geographically isolated valley located within the Appennine Mountains in Northwest Italy. The valley is inhabited by about 3,000 descendants from the original population, living in 7 villages along the valley and in the mountains. Participants were healthy people 18-102 years of age that had at least one grandfather living in the valley. The study plan and the informed consent form were reviewed and approved by the institutional review boards of San Raffaele Hospital in Milan.